This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on H2, 2015 Pipeline Review of “Esophageal Cancer” addition with 72 market data tables and 15 figures, spread across 355 pages is http://www.rnrmarketresearch.com/esophageal-cancer-pipeline-review-h2-2015-market-report.html .
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Discussed/Mentioned in this Research:
Adaptimmune Limited, Advantagene, Inc., Advaxis, Inc., Amgen Inc., ArQule, Inc., Array BioPharma Inc., Aslan Pharmaceuticals Pte. Ltd., AstraZeneca Plc, ATLAB Pharma SAS, AVEO Pharmaceuticals, Inc., Bayer AG, Boehringer Ingelheim GmbH, Celgene Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Cerulean Pharma, Inc., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Genmab A/S, Glycotope GmbH, Hutchison MediPharma Limited, Ignyta, Inc., ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomedics, Inc., Johnson & Johnson, Karyopharm Therapeutics, Inc., MacroGenics, Inc., Mebiopharm Co., Ltd., MedImmune, LLC, Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Precision Biologics, Inc., Proteo, Inc., Puma Biotechnology, Inc., Shionogi & Co., Ltd., Spectrum Pharmaceuticals, Inc., Symphogen A/S, Synta Pharmaceuticals Corp., Transgene Biotek Limited, VioQuest Pharmaceuticals, Inc., Virocan Therapeutics Private Limited and Zhejiang BetaPharma Co., Ltd.
Drugs Profile Discussed in this Research:
1-BB1, ADXS-HER2, afatinib dimaleate, alpelisib, AMG-337, ATL-101, binimetinib, CDX-1401, Cell Therapy 1 for Oncology, Cell Therapy to Target NY-ESO-1 for Oncology, cetuximab biobetter, CRLX-101, CYC-140, dacomitinib, DKN-01, durvalumab, elgemtumab, ficlatuzumab, futuximab, ganetespib, gedatolisib, gefitinib, Gene Therapy for Esophageal Cancer, Gene Therapy to Activate p53 for Oncology, HMPL-309, HuMax-TF-ADC, I131-CLR1404, icotinib hydrochloride, IMF-001, IMGN-289, JNJ-42756493, margetuximab, MBP-426, MMD-37K, MVXONCO-1, NEO-201, neratinib, nimotuzumab, nintedanib, nivolumab, OBP-301, OMN-54, paclitaxel albumin bound, panitumumab, pasireotide LAR, patritumab, PCA-062, pralatrexate, PTVICN-001, rAAV-VICN003, RXDX-106, S-588410, sacituzumab govitecan, selinexor, Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes, Small Molecule to Target LGR5 for Esophageal Adenocarcinoma, Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer, SMYD-2BAY02, TBL-0805E, tiprelestat, tivantinib, triciribine phosphate, Vaccine for Esophageal Cancer, Vaccine for Esophageal Cancer and Colorectal Cancer and varlitinib
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=439326 . (This is a premium report price at US$2000 for a single user PDF license)
- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on cancer Therapeutics Market.
Cancer has always being considered to be one of the dreadful diseases because of the deficiency in effective therapeutics. Every new day seems to be an opportunity for the researchers to find out a new reagent that can relieve the patients from the immense pain due to the malignant out growth. In fact the pharmaceutical industries have helped those inventions to reach out to the sufferers as fast as possible. Then only the invention will find its goal successfully: heal the mankind.
Thus various clinical trials of cancer therapeutics are being performed to bring the tremendous developments in to account. You might make the high prices to be the result of the new cancer treatment medicines entering the market. In recent years, the promising discoveries are being licensed as fast as possible such that it does not delay in reaching out to the ailing hands. You can also make this the sole reason for the pharmaceutical industry to reach its pinnacle during last few years.
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries